
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems is facing short-term challenges in regards to reimbursement and market uncertainty, leading to a downward revision in their revenue guidance for 2026. However, management has expressed confidence in their ability to return to revenue growth in 2027. The company's strong cash position, healthy gross margin, and expected profitability in the near term provide a solid foundation for the stock, but potential for multiple expansion is limited until there is greater visibility on future revenue growth.
Bears say
Inspire Medical Systems is facing significant headwinds in the near-term, with a recently announced reimbursement/coding disruption expected to impact revenues and profits. This, combined with long-term concerns about GLP-1 drugs and potential competition in the neurostimulation market, contribute to our negative outlook on the stock. While the recent launch of the Inspire V device is a positive development, the company's lowered guidance for FY2026 and challenging Q2 outlook make it difficult for us to remain optimistic about the stock's near-term prospects. As a result, we have downgraded our rating to Neutral and lowered our price target to $55, reflecting about 1x our FY27 revenue estimate.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares